Equity Profile

AXSM

Axsome Therapeutics, Inc.

Health CarePharmaceuticals$11.7B

Aug3Mon

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Axsome Therapeutics, Inc. is a pharmaceutical company focused on developing innovative therapies for central nervous system disorders....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health, which investors closely watch.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and commercialize its products effectively.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

AXSM Q2-2026 Earnings Preview

Context

Company Snapshot

Axsome Therapeutics, Inc. is a pharmaceutical company focused on developing innovative therapies for central nervous system disorders. With a market cap of $12 billion, it plays a significant role in the health care sector, particularly in addressing unmet medical needs in mental health and pain management.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-16.02%

Avg Stock Reaction

+2.10%

Last Quarter Recap

In Q1-2026, Axsome reported an EPS of -$1.26, which was worse than the expected -$0.85, leading to a significant surprise. Despite the miss, the stock rose by 8.31% the following day, indicating some investor optimism.

Management Promises & Guidance

Focus on advancing clinical trials for key products.
Commitment to improving operational efficiencies.
Plans to expand market access for existing therapies.

Expectations

Wall Street Expectations

Overall, expectations for Axsome's upcoming earnings are mixed, with no analyst estimates available. Investors are particularly interested in any updates regarding clinical trials and product launches.

Bull Case

If Axsome can demonstrate progress in its clinical trials and show better-than-expected revenue growth, it could lead to a strong positive reaction in the stock price.

Bear Case

Conversely, if the company reports larger-than-expected losses or delays in clinical trials, it could result in a negative reaction from investors.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of ongoing clinical trials for key therapies?

The outcome of these trials could significantly influence future revenue and market perception.

How does the company plan to address the recent EPS misses?

Investors will be keen to understand management's strategy to improve profitability and operational efficiency.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Axsome's pipeline to deliver positive results despite recent misses.

Supporting Evidence

The company's focus on central nervous system disorders positions it well in a growing market.

Recent insider selling may not reflect the overall potential of the company, as it could be part of a planned strategy rather than a lack of confidence.

Key Risk

If clinical trial results exceed expectations, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around Axsome's ability to manage costs while advancing its product pipeline.

Bull Confirmed If

A reduction in EPS losses to below -$1.00 would indicate improved operational performance.

Bear Confirmed If

An EPS loss greater than -$1.50 would confirm ongoing challenges in profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±19.2%

Historical Avg

±4.3%

Pricing rich

The options market is pricing in a significant potential move, suggesting that investors expect volatility around the earnings report.

Options are pricing ±19.2% while AXSM has averaged ±4.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

48.8%

Calls (91K)P/C Ratio: 0.88Puts (5K)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$1.4M

7,500 sh

1 insider

Net

$1.4M

Net selling

Most Active Insiders· 1 open-market trade

Chief Commercial OfficerMaizel Ari
$1.4M
Net selling

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Axsome beats expectations, history suggests a potential stock increase of around 2.93%, confirming a positive outlook.

In-Line / Cautious

If results are in line but cautious, the stock may see muted movement as investors digest the details.

Miss

A miss could lead to a decline, with historical data suggesting an average drop of 1.28% following negative surprises.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the timelines for key clinical trials.
2Any changes in guidance regarding revenue expectations.
3Details on cost management strategies.
4Insights into market access initiatives for existing products.
5Management's perspective on competitive landscape changes.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul31

SONYBMO

Sony Group Corporation

PreviewView

Jul31

ENBBMO

Company Snapshot

Axsome Therapeutics, Inc. is a pharmaceutical company focused on developing innovative therapies for central nervous system disorders....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health, which investors closely watch.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and commercialize its products effectively.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

AXSM Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-16.02%

Avg Stock Reaction

+2.10%

Last Quarter Recap

Management Promises & Guidance

Focus on advancing clinical trials for key products.
Commitment to improving operational efficiencies.
Plans to expand market access for existing therapies.

Expectations

Wall Street Expectations

Bull Case

If Axsome can demonstrate progress in its clinical trials and show better-than-expected revenue growth, it could lead to a strong positive reaction in the stock price.

Bear Case

Conversely, if the company reports larger-than-expected losses or delays in clinical trials, it could result in a negative reaction from investors.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of ongoing clinical trials for key therapies?

The outcome of these trials could significantly influence future revenue and market perception.

How does the company plan to address the recent EPS misses?

Investors will be keen to understand management's strategy to improve profitability and operational efficiency.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Axsome's pipeline to deliver positive results despite recent misses.

Supporting Evidence

The company's focus on central nervous system disorders positions it well in a growing market.

Recent insider selling may not reflect the overall potential of the company, as it could be part of a planned strategy rather than a lack of confidence.

Key Risk

If clinical trial results exceed expectations, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around Axsome's ability to manage costs while advancing its product pipeline.

Bull Confirmed If

A reduction in EPS losses to below -$1.00 would indicate improved operational performance.

Bear Confirmed If

An EPS loss greater than -$1.50 would confirm ongoing challenges in profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±19.2%

Historical Avg

±4.3%

Pricing rich

The options market is pricing in a significant potential move, suggesting that investors expect volatility around the earnings report.

Options are pricing ±19.2% while AXSM has averaged ±4.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

48.8%

Calls (91K)P/C Ratio: 0.88Puts (5K)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$1.4M

7,500 sh

1 insider

Net

$1.4M

Net selling

Most Active Insiders· 1 open-market trade

Chief Commercial OfficerMaizel Ari
$1.4M
Net selling

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Axsome beats expectations, history suggests a potential stock increase of around 2.93%, confirming a positive outlook.

In-Line / Cautious

If results are in line but cautious, the stock may see muted movement as investors digest the details.

Miss

A miss could lead to a decline, with historical data suggesting an average drop of 1.28% following negative surprises.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the timelines for key clinical trials.
2Any changes in guidance regarding revenue expectations.
3Details on cost management strategies.
4Insights into market access initiatives for existing products.
5Management's perspective on competitive landscape changes.